Warnex Becomes Canadian Distributor for Rosetta Diagnostic Tests | GenomeWeb

NEW YORK (GenomeWeb News) – Life sciences company Warnex and microRNA-based molecular diagnostics developer Rosetta Genomics announced today that Warnex Medical Laboratories has signed an exclusive agreement to distribute three of Rosetta's currently available diagnostic tests in Canada.

Under the agreement, Warnex will market the miRview mets test, the miRview squamous test, and the miRview meso test, and it will send Canadian samples to a CLIA-certified lab in Philadelphia for analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.